Abstract
Objective Greater accessibility to ambulatory services may mitigate emergency department (ED) presentations for lower acuity issues. This study examined ED utilization patterns for individuals with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) in a universal access healthcare setting.
Methods Linked population-based administrative datasets in Alberta, Canada (fiscal years 2007/2008-2017/2018) were assessed for yearly ED visit frequency, timing, triage acuity, most responsible diagnoses, and disposition for persons with PsA and r-axSpA.
Results A total of 4984 individuals with PsA and 14,690 with r-axSpA had 53,174 and 124,037 unique ED encounters, respectively. On average, 47.6% of persons with PsA and 35.7% with r-axSpA accessed the ED annually. Low acuity encounters (triaged as less urgent or nonurgent) were common, comprising 44.2% and 50.3% of visits for PsA and r-axSpA cohorts, respectively. Infection and injury were the most common responsible diagnoses. Presentations for inflammatory arthritis were infrequent (1.2% and 2% for PsA and r-axSpA cohorts, respectively), with no significant differences by sex or urbanicity. Rural patients had nearly twice the mean number of visits per year, had a higher frequency of less acute presentations, and were admitted less often in both disease cohorts. Sex differences included differential timing of presentation to EDs, and female patients with PsA had a lower frequency of admission relative to male patients with PsA.
Conclusion ED use for less urgent and nonurgent health concerns was frequent for persons with PsA and r-axSpA, particularly in rural settings. These data can inform tailored health service delivery including access solutions for persons residing in rural areas.
Quality health care aims to be safe, effective, patient-centered, timely, efficient, and equitable.1 Accessibility is also a pillar of high-quality health care, yet significant gaps in ambulatory care service delivery may drive patients to use urgent care and emergency departments (EDs) for unmet health needs.2,3 ED utilization for lower acuity and nonurgent issues indicates the necessity to more closely align ambulatory care provision with patient access needs.4-7
ED utilization data for people with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA; also known as ankylosing spondylitis) are scarce. An administrative claims-based study of individuals with r-axSpA in the United States reported the yearly prevalence of ED visits at 25% and all-cause inpatient admissions at 12.6% as compared to 15% and 6% among non–r-axSpA controls, respectively.8 Baser et al compared 3 datasets in the US over 2 years, with a range of 16.5% to 24.9% of individuals with r-axSpA visiting EDs and 5.1% to 6.3% hospitalized.9 A Canadian study examining Ontario administrative health data over 2 years estimated an all-cause ED presentation frequency of 43.5% for patients with r-axSpA, with a mean of 1 visit per year.10 The lowest reported prevalence of ED visits in a year for patients with r-axSpA was 3.5%, as reported by San et al.6 As for persons with PsA, the literature suggests an annual all-cause ED presentation prevalence of approximately 20%. For example, in a study by Greenberg et al examining administrative claims in the US, annual ED presentation and admission rates were 20.4% and 9.4% for a PsA cohort as compared to 22% and 11.1% among an r-axSpA cohort, respectively.11 However, these cited studies lack important characteristics about the ED visit and admission, particularly concerning acuity and responsible diagnoses, which could provide further insights with regard to how individuals access health care and their care outcomes.
The significant variability in data estimates and current gaps in knowledge of ED utilization indicate further research is needed to delineate trends and better inform health system planning with respect to persons with PsA and r-axSpA. The present study was designed to examine acute care health service utilization and variations by biological sex and geographic location among individuals with PsA and r-axSpA at a population level in the province of Alberta, Canada.
METHODS
Data source. Comprehensive administrative health datasets maintained by Alberta Health for the Alberta Health Care Insurance Plan (AHCIP) and Alberta Health Services were accessed. These datasets contain information about each patient interaction with the healthcare system from all sources for the province of Alberta, Canada (population of approximately 4.4 million people). Individual patient files are linked across datasets by a Unique Lifetime Identifier. Four datasets were accessed, beginning in fiscal year 2002/2003 and including up to fiscal year 2017/2018: the Discharge Abstract Database (hospitalizations), Practitioner Claims (outpatient physician visits), the National Ambulatory Care Reporting System (ED usage), and the Population Registry (demographic information).
Population. We constructed a cohort of individuals meeting a validated case definition for PsA,12 and a cohort of individuals meeting a validated case definition for r-axSpA.13 We omitted applying the physician type requirement of each definition owing to potential inaccuracies with the Alberta dataset specifying practitioner type. The case definitions are based on the International Classification of Diseases, 9th revision (ICD-9) codes recorded in physician claims data, and the ICD, 10th revision (ICD-10) codes recorded for hospitalization data. For PsA, applicable codes were ICD-9, Clinical Modification (ICD-9-CM) 696.X and 720.X, ICD-10, Canadian modification (ICD-10-CA) L40.X, M07.0, M07.1, M07.2, M07.3, M45.X or M09.0, with 1 hospitalization or at least 1 practitioner claim for psoriasis, and at least 2 practitioner diagnosis codes for spondyloarthritis ever, at any timepoint from 2002/2003 to 2017/2018. For r-axSpA, applicable codes were ICD-9-CM 720.X or ICD-10-CA M45.X, with 1 hospitalization or at least 2 practitioner claims in 2 years, for the same timepoints. We applied a 5-year washout period to create an incident cohort.
Outcomes. ED and urgent care center (UCC) visit outcomes were available from the National Ambulatory Care Reporting System dataset. The annual frequency of use of ED and/or UCC services by cases was estimated for each fiscal year from 2007/2008 to 2017/2018. To examine patterns of use, we assigned timing of visit as daytime (08:00 to 16:00), evening (16:01 to 22:00), or night (22:01-07:59) and the frequency of day of week utilized. Disposition outcomes included the length of stay in the department, ascertainment of admission to inpatient care, discharged or left without being seen, as well as return to ED within 72 hours. After extracting the acuity at presentation as assessed by triage personnel using the Canadian Triage and Acuity Scale (CTAS; 1: resuscitation, 2: emergent, 3: urgent, 4: less urgent, 5: nonurgent, and 9: unknown or missing)14 and the most responsible diagnosis as assigned by a health records nosologist reviewing physician documentation at time of ED discharge, larger diagnostic groupings were then assigned by authors who are both rheumatologists and health services researchers (CB and CEHB), as previously described.15 All primary analyses were repeated with stratification by sex (male or female as recorded in health administrative data) and location of residence (urban or rural/remote using 3-digit postal code information to determine the forward sortation area, with the second character indicating urban or rural residence).
Statistical analyses. Descriptive statistics were applied for frequency data, t tests for assessing significant differences by sex and location of residence in continuous data, and chi-square tests for categorical data. We concluded significant effects if P < 0.05. All analyses were completed using SAS (v9.4; SAS Institute).
RESULTS
Cohort demographics. The study population included 4984 persons with PsA and 14,690 persons with r-axSpA accrued over the 10-year period (Table 1). Mean age at the earliest visit for persons with PsA was 56.6 (SD 18.5) years, with 2325 (46.6%) recorded as female and 3885 (78%) residing at urban addresses. In the r-axSpA cohort, mean age at the earliest visit was 51.0 (SD 18.5) years, with 8094 individuals (55.1%) recorded as female and 10,960 (74.6%) residing at urban addresses.
Characteristics of individuals with PsA and r-axSpA with ED or UCC utilization in the province of Alberta (fiscal years 2007/2008-2017/2018).
Frequency of ED visits. There was a total of 53,174 and 124,037 unique ED or UCC visits by persons with PsA and r-axSpA, respectively. For persons with prevalent PsA and r-axSpA, 47.6% and 35.7% of the cohort accessed an ED or UCC each year, with the frequency being consistent over the 10-year study period. The annual mean number of visits per person decreased statistically in both cohorts, from 1.55 (95% CI 1.38-1.72) in fiscal year 2008 to 1.27 (95% CI 1.14-1.40) in fiscal year 2017 for the PsA cohort; and 1.10 (95% CI 1.02-1.17) in fiscal year 2008 to 0.94 (95% CI 0.90-0.98) in fiscal year 2017 for the r-axSpA cohort.
Visit characteristics. Among both PsA and r-axSpA cohorts, daytime presentations were more common (PsA 51.9% and r-axSpA 54.4%) than evening (PsA 28.5% and r-axSpA 29.5%) and nighttime (PsA 19.6% and r-axSpA 16.1%; Table 1). There was a similar distribution of ED or UCC presentations by day of the week for both the PsA and r-axSpA cohorts. The median length of ED stay increased from 180 (IQR 71-390) minutes in 2008 to 205 (IQR 89-425) minutes by 2017 for the PsA cohort, and from 118 (IQR 55-266) minutes in 2008 to 158 (IQR 79-309) minutes by 2017 for the r-axSpA cohort.
Acuity at presentation. Most visits were assessed as CTAS 4 (PsA 28.5% and r-axSpA 33%) and CTAS 5 (PsA 15.7% and r-axSpA 17.3%; Table 1). The proportion of visits triaged as nonurgent decreased for both cohorts over the 10-year study period, from 19.6% of all visits for the PsA cohort in 2008 to 13.6% in 2017, and from 21.3% in 2008 to 10.7% in 2017 for the r-axSpA cohort.
Visit diagnoses. Infections accounted for 11.7% of visits in both cohorts and most often received triage scores of CTAS 4 (PsA 37.6% and r-axSpA 44%) or CTAS 3 (PsA 35% and r-axSpA 28.9%; Table 2 and Table 3). Injury was responsible for 10.3% and 12.4% of all visits among the PsA and r-axSpA cohorts, respectively, primarily triaged as CTAS 4 (PsA 42.6% and r-axSpA 46.6%) and CTAS 3 (PsA 37.2% and r-axSpA 32.2%). Musculoskeletal (MSK) concerns accounted for 3.7% and 5.5% of diagnoses for individuals with PsA and r-axSpA, respectively, with inflammatory arthritis (IA) specifically recorded for 1.2% and 2% of presentations, respectively, the majority of which were triaged as CTAS 4 (PsA 42.3% and r-axSpA 39.3%) and CTAS 5 (PsA 15% and r-axSpA 18.8%).
Frequency of most responsible diagnosis stratified by CTAS emergency department or urgent care center utilization among individuals with psoriatic arthritis in the province of Alberta between fiscal years 2007/2008 and 2017/2018.
Frequency of most responsible diagnosis stratified by CTAS emergency department or urgent care center utilization among individuals with ankylosing spondylitis in the province of Alberta between fiscal years 2007/2008 and 2017/2018.
Disposition. The frequency of admission to an inpatient facility from the ED was 18.6% for PsA and 10.2% for r-axSpA, decreasing to 13% and increasing to 13.3% for PsA and r-axSpA, respectively, from 2008 to 2017 (Table 1). Visits with a diagnosis of IA resulted in admission for 0.8% of persons with PsA and 0.7% of those with r-axSpA. The specific diagnostic categories accounting for at least 5% of admissions among the PsA cohort were infection (16.3%) and injury (6.5%). For the r-axSpA cohort, the specific diagnostic categories accounting for at least 5% of admissions were infection (12.8%), injury (9.1%), gastrointestinal disease (8.6%), respiratory disease (6.8%), and major adverse cardiovascular (CV) events (5.7%). As for IA presentations, 30.2% of individuals with PsA and 18.9% with r-axSpA initially discharged from the ED/UCC returned within 72 hours.
Sex differences in ED use. On average, 47.8% of female and 47.4% of male individuals with PsA had an ED/UCC visit each year. As for the r-axSpA cohort, 38.5% of female and 32.5% of male individuals had an ED visit each year (Figure 1). Female patients with PsA more often presented during daytime hours (54.1% vs male 50%) and less frequently overnight (16.7% vs male 22%; P < 0.001). In the r-axSpA cohort, daytime presentation was similar between female and male patients (54.5% and 54.3%), with slightly more female patients during evening hours (30.9% vs 27.3%) and slightly less overnight (14.7% vs 18.4%). In all years for both PsA and r-axSpA cohorts, acuity level at presentation was similar between female and male patients. In the PsA cohort, female patients were less likely to be admitted than male patients (17.8% vs 19.3%; difference 1.5%, 95% CI 0.8-2.1%; P < 0.001).
Emergency department and urgent care center utilization by percentage of 14,690 male and female patients with radiographic axial spondyloarthritis in the province of Alberta between fiscal years 2007/2008 and 2017/2018. Shading represents 95% CIs.
Although reasons for presentation were consistent between sexes, male PsA cases had more visits labeled as substance use disorder than female cases (5.7% vs 1.7%; difference 4%, 95% CI 3.7-4.4%; P < 0.001). Among the r-axSpA cohort, the neurologic diagnostic category accounted for 6.3% of visits for female patients and 3.8% of visits for male patients (difference 2.5%, 95% CI 2.3-2.8%; P < 0.01).
Geographic location of residence differences in ED use. Rural PsA cases were significantly more likely to have at least 1 ED presentation per year (63.5%) than urban PsA cases (43.6%; Figure 2). Rural residents had a significantly higher mean number of visits per year (mean 2.1 [SD 8.4]) compared to urban residents (mean 1.1 [SD 3.3], P < 0.001). Rural r-axSpA cases more frequently had at least 1 ED presentation per year (51.7% rural vs 31.2% urban; Figure 3) and approximately twice the number of mean yearly ED/UCC visits (1.5 [SD 4.2] vs 0.8 [SD 2.0], P < 0.001).
Emergency department and urgent care center utilization by percentage of 4984 rural and urban patients with psoriatic arthritis in the province of Alberta between fiscal years 2007/2008 and 2017/2018. Shading represents 95% CIs.
Emergency department and urgent care center utilization by percentage of 14,690 rural and urban patients with radiographic axial spondyloarthritis in the province of Alberta between fiscal years 2007/2008 and 2017/2018. Shading represents 95% CIs.
Rural persons with PsA more often visited the ED during daytime hours (59.8% vs urban 47.8%) than evening (26.5% vs 29.6%) and nighttime hours (13.7% vs 22.6%), and were more likely to visit the ED during a regular weekday (73.1% vs 69.8%) and less likely on weekends or holidays (26.9% vs 30.2%). Patients with r-axSpA residing in rural settings likewise presented more frequently during daytime hours (57.9% vs urban 51.8%) than evening (29.2% vs urban 29.7%) and nighttime hours (12.9% vs urban 18.5%). Patients from urban settings had approximately twice as long median ED stays compared to rural patients in both the PsA (median 245 mins vs rural median 102 mins) and r-axSpA cohorts (median 179 mins vs rural 86 mins; P < 0.001).
Persons with PsA in rural settings were more often assessed as CTAS 5 (nonurgent: 28.6% vs urban 9.1%) or CTAS 4 (less urgent: 32.1% vs urban 26.6%) and less often CTAS 1 (resuscitation: 0.5% vs 1%), CTAS 2 (emergent: 6.1% vs 18.9%), or CTAS 3 (urgent: 21.7% vs 41.9%). These proportions were similar among the rural r-axSpA cohort. Residents from urban areas were more often admitted to hospital among the PsA (21.3% vs rural 13.5% of ED visits, difference 7.7%, 95% CI 7.1-8.4%; P < 0.001) and r-axSpA cohorts (12.4% vs rural 7.3%, difference 5.1%, 95% CI 4.8-5.4%; P < 0.001). Re-presentation within 72 hours was more common in rural persons (PsA 30.1% rural vs 20.2% urban; r-axSpA 24.6% rural vs 18.4% urban). More patients left without being seen in rural settings (both r-axSpA and PsA 0.4% rural vs 0.1% urban).
The most common specific diagnostic categories for the PsA cohort were infection (PsA rural 11.9% vs urban 11.6%) and injury (PsA rural 8.8%, urban 11%), whereas for r-axSpA, the categories were injury (r-axSpA rural 9.6% vs urban 14.5%) and infection (r-axSpA rural 11.5% vs urban 11.8%). The next most common diagnosis in the PsA cohort for rural patients was MSK conditions (3.6%), and for urban patients, it was substance use disorder (4.7%). In the r-axSpA cohort, the next most frequently assigned diagnosis was neurologic for rural persons (6.4%) and MSK for urban persons (5.3%). Inflammatory arthritis was the most responsible diagnosis for 1.1% of urban vs 1.3% of rural presentations in patients with PsA, and for 1.8% of urban vs 2.3% of rural presentations in persons with r-axSpA.
DISCUSSION
We examined utilization and characteristics of ED use by persons with PsA and r-axSpA. We found that half of ED visits were triaged as less urgent or nonurgent, with the most prevalent reasons for presentation being for symptoms that could not be attributed to a specific diagnosis. Injuries and infections accounted for just over 10% of ED visits each, with IA as the most responsible diagnosis, having a significant number of return visits but with admission being relatively rare. Persons from rural settings had nearly twice the mean number of visits per year and were more often triaged as less acute, more frequently returned to ED within 72 hours, and were less frequently hospitalized compared to their urban counterparts. We also identified sex differences in ED use, including female individuals presenting more often during daytime hours compared to male individuals, and a lower frequency of admission for female individuals with PsA relative to male individuals with PsA. These epidemiologic data provide insight into healthcare-seeking approaches among persons with PsA and r-axSpA, particularly with respect to the striking differences in ED utilization patterns between rural and urban settings. Our findings add to the mounting evidence for areas of improvement in the provision of ambulatory care for the timely assessment of less urgent and nonurgent issues, especially with acute care resources being increasingly under strain.7
The frequency of ED utilization among both cohorts in our study, which was stable over a decade similar to general ED utilization trends in Canada,7 was at least double the annual prevalence in other PsA and r-axSpA cohort reports from the US8,9,11 and Ontario, Canada.10 These differences could relate to context-specific factors. For example, there could be increased utilization of acute care services in the universal healthcare model existing in Canada, as it has reduced cost barriers relative to the US. Interprovincial variability of ED utilization within Canada is evident, with a lower overall acuity of ED presentations in Alberta compared to Ontario.16 The yearly proportion of individuals hospitalized in our study likewise exceeds previous reports from the US,8,9,11 which has been attributed to a relative lack of acute care beds and longer duration of hospitalization in Canada compared to other economically developed countries.7 Causes for the prevalence of acute care use being the most pronounced for individuals with PsA compared to r-axSpA remain to be examined. Other factors driving ED utilization and overcrowding among persons with IA, such as lack of ambulatory care capacity and accessibility,7,11 would presumably affect individuals in a similar fashion, regardless of PsA or r-axSpA diagnosis.
Between these 2 conditions, we did not observe major differences in key diagnostic categories at ED presentation, such as major adverse CV events, as might be expected with the prevalence of cardiometabolic comorbidity among those with PsA,17 though elevated CV risk for individuals with r-axSpA is also increasingly recognized.18,19 Other categories with relevance to disease manifestations and treatment outcomes, such as IA, dermatologic, gastrointestinal, and infectious diagnoses, were similar. Taken together, this trend suggests greater all-cause acute care utilization for persons with PsA vs r-axSpA, which stands in contrast to prior literature finding similar proportions of ED utilization and admission between patients with PsA and r-axSpA in the US.11
Finally, the greater reliance on ED services in rural settings in both cohorts may reflect reduced accessibility to ambulatory care, which previous research has correlated with preventable acute care.20-22 Alternatively, the prevalence of weekday and daytime presentations to rural EDs may be partly explained by rural primary care physicians (PCPs) seeing patients in those settings while they are simultaneously staffing the ED. The higher rates of return to ED within 72 hours in rural settings may be similarly explained by context-specific factors such as patients intentionally returning when services such as diagnostic imaging become available during daytime weekday hours. Although not statistically significant, we observed a slight trend toward more frequent IA presentations for rural patients in both cohorts, which may signal worse disease outcomes among rural patients, who are known to face significant disparities in access to rheumatology care relative to their urban counterparts.23
The present study signals gaps in healthcare provision for individuals with rheumatologic concerns including PsA and r-axSpA, with implications for other groups with complex chronic medical conditions navigating the healthcare system. High acute care use often indicates shortcomings in ambulatory care accessibility—in this context reflecting both rheumatology specialty care and primary care—to address nonurgent and disease-specific issues. The shortage of PCPs is well known, with recent Canadian research estimating 1 in 5 people nationally, and a similar portion of those residing in Prairie provinces such as Alberta, as not having a PCP.24 Access barriers to ambulatory rheumatologic care are well established.25 Increased and sustained investments in training and retaining rheumatology and PCPs, improved information technology, and creative solutions for optimizing workflow including payment and care models supporting interprofessional care, are indicated.7,26 Sex- and gender-specific aspects such as differential access to care, prescribing, and response to therapies are also described in patients with PsA and r-axSpA, among other systemic autoimmune rheumatic diseases, and need to be addressed accordingly in designing accessible models of care. Patient education programs could include information about when and how to seek urgent reassessments for disease flares. Innovative solutions that are proposed include implementation of patient navigation technology and personnel, involvement of allied health and extended role practitioners, telemedicine, and adapting current training programs and practice models to increase the presence of rheumatology expertise in these communities.23,27
These findings should be considered in the context of several strengths and limitations of our study. A control population was not provided by the data stewards, but comparing the results obtained in the PsA and r-axSpA cohorts relative to the general population would be of interest for future research. The extended run-in period to ascertain incident cases with a decade of follow-up data allows for longitudinal evaluation of ED utilization compared to previous literature, which is largely limited to a constrained 1-year or 2-year sampling. Our study also used a large population-based universal healthcare dataset that captures all acute care interactions and more granular details such as time and day of presentation, triage acuity, and most responsible diagnosis of both initial presentation and 72-hour return to ED, which is lacking in previous similar research. We used validated case definitions to accurately identify PsA and r-axSpA, but the nature of the large dataset nonetheless brought other inherent coding limitations, such as the large proportion of nonspecific diagnoses; the exact effect of this limitation is unclear as these categories could conceivably apply to a range of specific informative ED diagnoses from infection to IA. Other important variables such as comorbidity, pertinent investigations and medications, primary care and rheumatology provider linkage, disease activity, and socioeconomic factors were also not available and would strengthen future research. Last, a cost analysis was not possible with our dataset and would be a valuable aspect for future study as others have shown increased and variable office visit, ED, and hospitalization costs among patients with PsA and r-axSpA.11
In conclusion, in this retrospective study of linked population-based administrative health data in the province of Alberta, Canada, infections and injuries comprised the most frequent responsible diagnoses. Approximately half of persons with PsA and r-axSpA presenting to ED were triaged as less urgent and nonurgent acuity. This was more common in rural areas, as was more frequent re-presentation and hospitalization. These findings highlight areas for improvement in providing urgent and primary care services for persons with PsA and r-axSpA, particularly in rural locations, to optimize utilization of limited healthcare resources.
Footnotes
CONTRIBUTIONS
Conceptualization, funding acquisition, writing - review and editing: CEHB, CB, KC, ED, MJE, CH, BRH, SK, EL, KL, PM, SM, NR; methodology: CEHB, CB, MJE, BRH, SK, EL, KL, PM; data curation, investigation, project administration, supervision: CB; formal analysis and writing of original draft: VM, CB; visualization: VM.
FUNDING
This study was supported by the Canadian Institutes of Health Research Project Grant, Priority Announcement in Patient-Oriented Research (competition 202109PJK, application no. 474410).
COMPETING INTERESTS
The authors declare no conflicts of interest relevant to this article.
ETHICS AND PATIENT CONSENT
The University of Calgary Conjoint Health Research Ethics Board approved the study (ethics ID REB20-0357) and administrative approval from Alberta Health Services was granted in March 2021. A waiver of individual patient consent was approved related to the nature of the dataset.
- Accepted for publication December 16, 2024.
- Copyright © 2025 by the Journal of Rheumatology